Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Topadur Pharma AGStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | CH | - | |
Colorectal Cancer | Preclinical | CH | Topadur Pharma AGStartup | - |
Colorectal Cancer | Preclinical | CH | - | |
Diabetic Retinopathy | Preclinical | CH | Topadur Pharma AGStartup | - |
Dystrophy, Macular | Preclinical | CH | Topadur Pharma AGStartup | - |
Idiopathic Pulmonary Fibrosis | Preclinical | CH | Topadur Pharma AGStartup | - |
Inflammatory Bowel Diseases | Preclinical | CH | Topadur Pharma AGStartup | - |
Pulmonary Arterial Hypertension | Preclinical | CH | Topadur Pharma AGStartup | - |